2012, Number 3
Intravitreal injections to prevent blindness due to wet type age-related macular degeneration
Pérez MEC, Rodríguez DF, Guillen BME
Language: Spanish
References: 8
Page:
PDF size: 20.75 Kb.
ABSTRACT
A research on a novel treatment used in wet type age-related macular degeneration – a common cause of irreversible blindness worldwide – was conducted with the aim of raising awareness of its effectiveness according to evidence-based studies performed by prestigious health institutions. The technique is the use of intravitreal injections of lucentis (bevacizumab) and avastin (monoclonal antibodies) to neutralize the biological activity of the growth factor of the vascular endothelium and to reduce vascular permeability. The long-term post intravitreal positive effects are shown, and the possibility of using a more economical drug with similar visual results.REFERENCES
Arantes Tiago FE, Vinícius Paganini N, Otacílio de Oliveira MJ, Walter Yukihiko T. Bevacizumab (Avastin®) no tratamento da membrana neovascular coroidal secundária à degeneração macular relacionada à idade: relato de caso. Arq Bras Oftalmol [serial on the Internet]. 2007 dec [cited 2012 Sep 21]; 70(6): 1016-20. Available from: http://www.scielo.br/scielo.php?pid=S000427492007000600025&script=sci_arttext